| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory | Frank Vinluan | 04/23/20 | Boston |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy | Frank Vinluan | 01/08/20 | San Francisco |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
| PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome | Frank Vinluan | 06/26/19 | Boulder/Denver |
| With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease | Frank Vinluan | 06/10/19 | Boston |
| With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes | Frank Vinluan | 05/30/19 | San Francisco |
| Kaleido Bio Downsizes IPO, Raises $75M for Microbiome Drug Tests | Frank Vinluan | 02/27/19 | Boston |
| Gates Foundation, Bristol-Myers Join $27M Funding for Vedanta Bio | Frank Vinluan | 12/24/18 | Boston |
| Xenex Adds $4.8M for Hospital Trial Program of Germ-Zapping Robots | David Holley | 10/09/18 | Texas |
| With FDA’s Blessing, Seres Preps New “Pivotal” Microbiome Drug Trial | Frank Vinluan | 03/16/17 | Boston |
| Xenex Gets $38M From Essex Woodlands, Others for Germ-Zapping Robots | David Holley | 02/24/17 | Texas |
| Seres Dissects Failed Microbiome Drug Trial, Suggests Changes to FDA | Frank Vinluan | 01/31/17 | Boston |
| U-M Gets $2M to Study Xenex Robots’ Ability to Sanitize Hospitals | David Holley | 01/12/17 | Texas |
| Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More | Alex Lash | 07/29/16 | National |
| In a Microbiome Setback, Seres Drug Fails in Phase 2, Shares Crushed | Ben Fidler | 07/29/16 | Boston |
| With Bugs As Drugs, Evelo CEO Plans Immune, Cancer Trials in 2017 | Alex Lash | 07/12/16 | Boston |
| Vedanta Nabs $50M To Expand Microbiome Into Immune-Boosting Therapies | Ben Fidler | 06/06/16 | Boston |
| From Adviser to CEO: Morris Miller on Xenex’s Disinfecting Robots | David Holley | 11/25/15 | Texas |
| Five Takeaways From “Boston’s Life Science Disruptors” | Ben Fidler | 10/02/15 | Boston |
| Bon Appetit: Seres And Its Microbiome Gut Treatment Notch $134M IPO | Alex Lash | 06/25/15 | Boston |
| Gold Bugs? Seres Files For First IPO of Human Microbiome Era | Alex Lash | 05/27/15 | Boston |
| One Week Into The New Year, Five Biotechs Reel in $220M Venture Cash | Alex Lash | 01/08/15 | National |
| Don’t Get Comfortable: 5 Biopharma Flashpoints to Consider in 2015 | Alex Lash | 01/06/15 | National |
| Independent No More: Cubist Sold to Merck for $9.5B | Ben Fidler | 12/08/14 | Boston |
| With Crossover Cash, Seres Health Aims For Big Microbiome Milestones | Alex Lash | 12/02/14 | Boston |
| Ebola Outbreak a Proving Ground for Lucigen’s Rapid Diagnostic | Jeff Bauter Engel | 11/03/14 | Wisconsin |
| Cubist CEO Bonney Steps Down After 12-Year Stint | Ben Fidler | 10/20/14 | Boston |
| J&J Immunology Exec on Investing at the Crossroads of the Microbiome | Ben Fidler | 07/24/14 | National |
